Kymera Therapeutics

Edit info

Founded: 2017

Location: Watertown, MA

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: Immuno-inflammatory diseases

Drug types: IMM, RHU, DRM, ONC,LNG, GI, NEU

Lead product: KT-474 (partner: Sanofi)

Funding: $150M stock Aug 2022; $223M stock Jul 2021; $200M IPO Aug 2020; $102M C Mar 2020; $70M May 2019; $65M Nov 2018; $30M Dec 2017

Investors: Biotechnology Value Fund, Redmile Group

kymeratx.com

linkedin.com

job board

Business:

Small Molecules acting to degrade proteins

Drug notes:

KT-413 Clin1 oncology; KT-333 Clin1 multiple cancers; KT-253 Clin0 multiple cancers; 5 undisclosed programs RD autoimmune & fibrotic diseases, immune-inflammatory diseases, oncology

About:

Kymera Therapeutics is developing novel protein degrader therapeutics to treat disease. Cells possess various ways to selectively degrade proteins. Kymera is harnessing these natural processes to selectively degrade disease causing proteins to remove them from the body. To identify effective methods, Kymera is using their proprietary targeted protein degradation platform, Pegasus, which enables the design of highly selective, heterobifunctional small molecule protein degraders. Pegasus works by combining E3 Ligase whole-body expression levels and binders with quantitative system pharmacology. Kymera’s investigational drugs are in development to treat a broad range of immune-inflammatory diseases, hematologic malignancies and solid tumors.

Vice President, Safety and Pharmacovigilance

Watertown, MA|3 days ago